Search research articles
Contact Us
Filters
Showing results (671-680 of 680) with videos related to
Page
of 68
Sort By:
You have reached the last page of results.
This site can display upto 680 results.
The New England Journal of Medicine
|
September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Ann R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
The Lancet. HIV
|
March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting
Boris Julg, Lynda Dee, Jintanat Ananworanich, et al.
Cell Reports
|
August 10, 2023
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes
Rajeshwer S Sankhala, Vincent Dussupt, Gina Donofrio, et al.
Plos One
|
November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Plos Pathogens
|
August 4, 2015
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
Sampa Santra, Georgia D Tomaras, Ranjit Warrier, et al.
Lancet (London, England)
|
July 27, 2018
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Dan H Barouch, Frank L Tomaka, Frank Wegmann, et al.
Journal of Virology
|
May 16, 2014
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial
Andrew J Gartland, Sue Li, John McNevin, et al.
Lancet (London, England)
|
January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
Melinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
Nature Medicine
|
February 5, 2020
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor
Vincent Dussupt, Rajeshwer S Sankhala, Gregory D Gromowski, et al.
Immunity
|
March 17, 2019
Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual
Shelly J Krebs, Young D Kwon, Chaim A Schramm, et al.
Page
of 68
Search research articles
Search
Showing results (671-680 of 680) with videos related to
Sort By:
Page
of 68
You have reached the last page of results.
This site can display upto 680 results.
The New England Journal of Medicine
|
September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Ann R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
The Lancet. HIV
|
March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting
Boris Julg, Lynda Dee, Jintanat Ananworanich, et al.
Cell Reports
|
August 10, 2023
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes
Rajeshwer S Sankhala, Vincent Dussupt, Gina Donofrio, et al.
Plos One
|
November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Plos Pathogens
|
August 4, 2015
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
Sampa Santra, Georgia D Tomaras, Ranjit Warrier, et al.
Lancet (London, England)
|
July 27, 2018
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)
Dan H Barouch, Frank L Tomaka, Frank Wegmann, et al.
Journal of Virology
|
May 16, 2014
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial
Andrew J Gartland, Sue Li, John McNevin, et al.
Lancet (London, England)
|
January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
Melinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
Nature Medicine
|
February 5, 2020
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor
Vincent Dussupt, Rajeshwer S Sankhala, Gregory D Gromowski, et al.
Immunity
|
March 17, 2019
Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual
Shelly J Krebs, Young D Kwon, Chaim A Schramm, et al.
Page
of 68